Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radioimmunotherapy with alpha-emitting nuclides

M R McDevitt1, G Sgouros, R D Finn

  • 1Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

European Journal of Nuclear Medicine
|September 2, 1998
PubMed
Summary

This review explores alpha particle-emitting radionuclides for targeted radioimmunotherapy. These isotopes offer selective cancer cell killing, with promising preclinical and clinical applications in antibody-drug conjugates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiation segmentectomy of hepatic metastases with Y-90 glass microspheres.

Abdominal radiology (New York)·2021
Same author

KRAS mutation effects on the 2-[18F]FDG PET uptake of colorectal adenocarcinoma metastases in the liver.

EJNMMI research·2020
Same author

Dermanyssus gallinae and chicken egg production: impact, management, and a predicted compatibility matrix for integrated approaches.

Experimental & applied acarology·2020
Same author

A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies.

Leukemia·2017
Same author

CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes.

Leukemia·2017
Same author

Poster - Thurs Eve-11: Quantitative imaging of 213Bi alpha-emitter with a beta-imager.

Medical physics·2017

Area of Science:

  • Nuclear medicine
  • Radiopharmaceutical chemistry
  • Oncology

Background:

  • Targeted radioimmunotherapy utilizes radionuclides conjugated to antibodies for cancer treatment.
  • Alpha particle emitters offer high cytotoxicity due to their high linear energy transfer and short range.
  • Several alpha-emitting isotopes are being investigated for clinical applications.

Purpose of the Study:

  • To review the application of alpha particle-emitting radionuclides in targeted radioimmunotherapy.
  • To outline the production and chemistry of key alpha-emitting isotopes.
  • To discuss dosimetric methodologies and clinical use of these agents.

Main Methods:

  • Review of literature on alpha particle-emitting radionuclides.
  • Discussion of production and chemical properties of selected isotopes (e.g., Ac-225, Bi-213, Ra-223, At-211).

Related Experiment Videos

  • Analysis of pharmacokinetic data and dosimetric approaches for radioimmunoconstructs.

    • Main Results:

    • Identified key alpha-emitting radionuclides (Ac-225, Bi-213, Ra-223, At-211, etc.) as promising for clinical use.
    • Highlighted the selective cytotoxicity mechanism of alpha emitters.
    • Summarized preclinical and initial clinical data of alpha-emitting radioimmunoconstructs.

    Conclusions:

    • Alpha particle-emitting radionuclides hold significant potential for targeted cancer therapy.
    • Further research in production, chemistry, and clinical application is warranted.
    • Radioimmunoconjugates with alpha emitters show promise for treating human neoplasia.